+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Migraine - Pipeline Insight, 2021

  • ID: 4989373
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • AbbVie
  • Allodynic Therapeutics
  • Eli Lilly and Company
  • Pharmaleads
  • Satsuma Pharmaceuticals
  • Vaxxinity
  • MORE
This “Migraine - Pipeline Insight, 2021” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Migraine Understanding

Migraine: Overview

Migraine is a medical condition that involves severe, recurring headaches and other symptoms. Before the headache, there may be sensory changes that are known as an aura. A migraine is a type of headache with symptoms that can differ from those of non-migraine headaches. These may include unusual symptoms that can be scary, like tingling sensations, flashing lights, weird sounds, and blurred or lost vision.

There's no cure for migraine headaches. But many drugs can treat or even prevent them. Common migraine treatments include: Pain relief- Over-the-counter (OTC) drugs often work well. The main ingredients are acetaminophen, aspirin, caffeine, and ibuprofen. Triptans- These drugs balance the chemicals in brain, includes almotriptan (Axert), eletriptan (Relpax), sumatriptan (Imitrex), rizatriptan (Maxalt), and zolmitriptan (Zomig).

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Migraine R&D. The therapies under development are focused on novel approaches for Migraine.
Migraine Emerging Drugs Chapters

This segment of the Migraine report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Migraine Emerging Drugs

Zavegepant: Biohaven Pharmaceuticals

Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration.

It is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals.

STS-101: Satsuma Pharmaceuticals

STS101 (dihydroergotamine mesylate (DHE) nasal powder) for the acute treatment of migraine is Satsuma Pharmaceuticals' lead product candidate. Both STS101 dosage strengths were well-tolerated in the EMERGE trial, with low adverse event rates and no serious adverse events reported.

It is currently in Phase III stage of development for Migraine and is being developed by Satsuma Pharmaceuticals.

Migraine: Therapeutic Assessment

This segment of the report provides insights about the different Migraine drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Migraine

There are approx. 30+ key companies which are developing the Migraine. The companies which have their Migraine drug candidates in the most advanced stage, i.e. Phase III include, Biohaven Pharmaceuticals.

Phases

This report covers around 30+ products under different phases of clinical development like
  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Migraine: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Migraine therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Migraine drugs.

Migraine Report Insights
  • Migraine Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Migraine Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Scenario and Emerging Therapies:
  • How many companies are developing Migraine drugs?
  • How many Migraine drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Migraine?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Migraine therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Migraine and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Satsuma Pharmaceuticals
  • Biohaven Pharmaceuticals
  • Allodynic Therapeutics
  • Vaxxinity
  • AbbVie
  • Pulmatrix
  • AEON Biopharma
  • Eli Lilly and Company
  • Trevena
  • Xoc Pharmaceuticals
  • Pharmaleads
  • Pear Therapeutics
Key Products
  • STS-101
  • Zavegepant
  • ALLOD-2
  • UB-313
  • Atogepant
  • PUR-3100
  • ABP-450
  • LY3451838
  • TRV250
  • XC101
  • PL37


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • Allodynic Therapeutics
  • Eli Lilly and Company
  • Pharmaleads
  • Satsuma Pharmaceuticals
  • Vaxxinity
  • MORE
Introduction

Executive Summary

Migraine: Overview
  • Structure
  • Mechanism of Action
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Migraine- Analytical Perspective

In-depth Commercial Assessment
  • Migraine companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Migraine Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Zavegepant: Biohaven Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
LY3451838: Eli Lilly and Company
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
TRV250: Trevena
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
PUR-3100: Pulmatrix
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Migraine Key Companies

Migraine Key Products

Migraine- Unmet Needs

Migraine- Market Drivers and Barriers

Migraine- Future Perspectives and Conclusion

Migraine Analyst Views

Migraine Key Companies

Appendix

List of Tables
Table 1 Total Products for Migraine
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Migraine
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Satsuma Pharmaceuticals
  • Biohaven Pharmaceuticals
  • Allodynic Therapeutics
  • Vaxxinity
  • AbbVie
  • Pulmatrix
  • AEON Biopharma
  • Eli Lilly and Company
  • Trevena
  • Xoc Pharmaceuticals
  • Pharmaleads
  • Pear Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll